Skip to main content

Table 1 Demographic Data (Treated Set)

From: Efficacy and Safety Results of the Afatinib Expanded Access Program

Characteristic Afatinib 40 mg, N = 322
Gender, n (%)
 Female 221 (68.6)
 Male 101 (31.4)
Race, n (%)a
 White 237 (73.6)
 Asian 56 (17.4)
 Black/African American 24 (7.5)
 Native Hawaiian/Pacific Islander 2 (0.6)
 American Indian/Alaska Native 2 (0.6)
Age, mean (SD), years 64.6 (12.1)
 Min; max 35; 94
Smoking status, n (%)
 Never smoked 201 (62.4)
 Ex-smoker 113 (35.1)
 Currently smokes 8 (2.5)
Baseline ECOG score, n (%)
 0 112 (34.8)
 1 168 (52.2)
 2 42 (13.0)
TKI status, n (%)  
 Exposedb 281 (87.3)
 Naïve 41 (12.7)
  First-line afatinib 23 (7.1)
Common EGFR mutation, n (%) 267 (82.9)
Uncommon EGFR mutation, n (%)c 55 (17.1)
 T790M 25 (7.8)
 Exon 20 insertions 22 (6.8)
 G719S, G719A, G719C 20 (6.2)
 L861Q 13 (4.0)
 S768I 4 (1.2)
 Other—not specified 13 (4.0)
Time since first diagnosis, mean (SD), months 32.8 (28.0)
 Min; max 1; 152
Histologic classification, n (%)
 Predominantly adenocarcinoma 303 (94.1)
 NOS 8 (2.5)
 Predominantly squamous cell carcinoma 7 (2.2)
 Large cell/undifferentiated carcinoma 4 (1.2)
Clinical stage at initial diagnosis, n (%)d
 0–IIB 54 (16.8)
 IIIA 24 (7.5)
 IIIB 23 (7.1)
 IV 218 (67.7)
  1. SD standard deviation, ECOG Eastern Cooperative Oncology Group, TKI tyrosine kinase inhibitor, EGFR epidermal growth factor receptor, NOS not otherwise specified
  2. aData missing for one patient
  3. bAll except two patients received erlotinib
  4. cPatients can appear in ≥1 category
  5. dData missing for three patients